Description
Tirzix 5 mg
Generic Name: Tirzepatide
Strength: 5 mg
Manufacturer: Beacon Pharmaceuticals Ltd.
Form: Subcutaneous Injection (Prefilled Pen or Vial)
Description:
Tirzix 5 mg contains Tirzepatide, a novel dual agonist of GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. It is used as a once-weekly injectable medication primarily indicated for type 2 diabetes mellitus and shows promising results in weight management and metabolic control.
Tirzix offers a unique mechanism that enhances insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite — contributing to better glycemic control and significant weight loss benefits.
Indications:
-
Type 2 Diabetes Mellitus (as adjunct to diet and exercise)
-
Obesity and overweight management (off-label, under clinical guidance)
Dosage & Administration:
-
Starting dose: 2.5 mg once weekly (typically increased every 4 weeks)
-
Maintenance dose: 5 mg to 15 mg once weekly, based on patient tolerance and therapeutic goal
-
Administered subcutaneously in the abdomen, thigh, or upper arm
Pharmacology:
Tirzepatide mimics the action of GIP and GLP-1, stimulating insulin release and improving glycemic control. Its dual agonism leads to enhanced metabolic outcomes compared to traditional GLP-1 therapies.
Side Effects:
-
Nausea, vomiting, diarrhea
-
Decreased appetite
-
Injection site reactions
-
Hypoglycemia (especially when used with insulin or sulfonylureas)
Contraindications:
-
Personal or family history of medullary thyroid carcinoma (MTC)
-
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
-
Hypersensitivity to tirzepatide or excipients
Storage Conditions:
-
Store in a refrigerator (2°C to 8°C)
-
Do not freeze
-
Protect from light
Therapeutic Class:
GLP-1 Receptor Agonist / Dual Incretin Receptor Agonist
Reviews
There are no reviews yet.